Clinical development of a cyclosporine microemulsion in transplantation

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 429-434

  Kovarik, John M ^a   Mueller, Edgar A ^a   Niese, Detlef ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

Cyclosporine; Drug development; Drug formulation; Microemulsion; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOOD DRUG INTERACTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG DESIGN; EMULSIONS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 0029830648     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00020     Document Type: Conference Paper

References (19)

1. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993:54:205-18.
2. Canafax D. Minimizing cyclosporine concentration variability to optimize transplant outcome. Clin Transplant 1995; 9:1-13.
3. Ritschel WA, Adolph S, Ritschel GB, Schroeder T. Improvement of peroral absorption of cyclosporine A by microemulsions. Methods Find Exp Clin Pharmacol 1990;12:127-34.
4. Reymond J-P, Sucker H. In vitro model for cyclosporin intestinal absorption in lipid vehicles. Pharm Res 1988;5:673-6.
5. Reymond J-P, Sucker H, Vonderscher J. In vivo model for cyclosporin intestinal absorption in lipid vehicles. Pharm Res 1988;5:677-9.
6. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994;26:2925-7.
7. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301-4.
8. Grevel J. Absorption of cyclosporine A after oral dosing. Transplant Proc 1986;18(suppl 5):9-15.
9. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83:444-6.
10. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lücker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994;11:151-5.
11. Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13:613-7.
12. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 1994;57:1178-82.
13. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994;58:658-63.
14. Kovarik JM, Vernillet L, Mueller EA, Freiburghaus R, Niederberger W, Kutz K. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit 1994;16:519-25.
15. Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994;16:232-7.
16. Kovarik JM, Kallay Z, Mueller EA, van Bree JB, Arns W, Renner E. Acute effect of cyclosporine on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. Transplant Int 1995;8:335-9.
17. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transplant Int 1994;7(suppl 1):S263-6.
18. Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995;60:648-52.
19. Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporin pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation (in press).